Inhibikase Therapeutics Inc (IKT)

Inhibikase Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies intended to alter the course of cardiopulmonary diseases, with an emphasis on pulmonary arterial hypertension (PAH). The company’s lead program, IKT-001, is an oral prodrug of imatinib mesylate being developed for PAH with the aim of preserving systemic exposure and efficacy while improving tolerability. According to the company, IKT-001 has completed non-human primate safety work and a bioequivalence study in healthy volunteers, which showed dose equivalence with imatinib. The program is now under evaluation in the global adaptive Phase 3 IMPROVE-PAH trial, which includes measures such as pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics also has an exclusive license for IKT-001 and previously entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., later assigned to Pivot Holding LLC. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.